{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:04:18Z","timestamp":1790964258707,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Peripheral T\u2010cell lymphoma (PTCL) is a rare and heterogeneous group of diseases, with over 30 subtypes according to the International Consensus Classification of Mature Lymphoid Neoplasms (ICC) and World Health Organization Classification of Hematolymphoid Tumors (WHO\u2010HEM) 2022. The classification complexity reflects the underlying genetic and biological diversity of PTCL. For decades, distinct PTCL subtypes have been uniformly treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP\u2010like regimens originally developed for mainly B\u2010cell lymphoma. Attempts to improve frontline CHOP\u2010plus strategies have failed mainly due to toxicities and lack of biological rationale. Only the ECHELON\u20102 trial succeeded as more than 70% of patients had anaplastic large cell lymphoma (ALCL), where brentuximab vedotin (BV) is most effective. Looking ahead to 2025 and beyond, future treatment strategies for PTCL should be guided\u00a0by\u00a0a\u00a0deeper understanding of its underlying biology rather than relying on empirical extrapolations from other lymphomas.<\/jats:p>","DOI":"10.1002\/hon.70069","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T17:48:52Z","timestamp":1750009732000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peripheral T\u2010Cell Lymphoma: What's Next?"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-5297","authenticated-orcid":false,"given":"Sang Eun","family":"Yoon","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":false,"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0247-0"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100126"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025681"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/hemato5020013"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021786"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199304083281404"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol-20-35"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.012"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.007"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110429"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0838-5"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18885"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.742521"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12326"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00203-8"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.08"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0413"},{"issue":"18","key":"e_1_2_12_23_1","first-page":"2194","article-title":"Multicenter Phase 2 Study of Oral Azacitidine (CC\u2010486) Plus CHOP as Initial Treatment for PTCL","volume":"141","author":"Ruan J.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011095"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13855"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.003"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816700"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01687"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101160"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae144"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00554"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:36:47Z","timestamp":1760557007000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/hon.70069"],"URL":"https:\/\/doi.org\/10.1002\/hon.70069","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70069"}}